Semaglutide

FDA Approved

Weight Management

A GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and promotes significant weight loss with cardiovascular benefits.

Administration

Subcutaneous injection

Dosage Range

0.25-2.4 mg weekly (titrated)

Mechanism of Action

Semaglutide mimics GLP-1, binding to receptors in the brain's appetite center (hypothalamus) to reduce hunger, slow gastric emptying, and improve insulin sensitivity. It also has direct cardiovascular protective effects.

Clinical Benefits

Significant weight loss (15-20% body weight)

Improved glycemic control

Reduced cardiovascular risk

Lower blood pressure

Reduced inflammation

Clinical Evidence

FDA-approved for type 2 diabetes (Ozempic) and obesity (Wegovy). STEP trials demonstrated 15-17% weight loss. SELECT trial showed 20% reduction in major cardiovascular events.

Side Effects

Nausea

Vomiting

Diarrhea

Constipation

Abdominal pain

Contraindications

Personal/family history of medullary thyroid carcinoma

MEN 2 syndrome

Pancreatitis history

Pregnancy

Related Peptides in Weight Management

Tirzepatide

A dual GIP/GLP-1 receptor agonist that delivers superior weight loss and metabolic improvements compared to single-target therapies.

AOD-9604

A modified fragment of human growth hormone (hGH 176-191) that stimulates fat metabolism without the growth-promoting effects of full GH.

MOTS-c

A mitochondrial-derived peptide that acts as an exercise mimetic, improving metabolic function and insulin sensitivity.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.